Summary of Webinar - 10/06/22
- 17 million cash, no debt
- They are advancing towards FDA approval within the next 18-24 months
- They have strong distribution/manufacturing partners for global expansion
- Expanding their market share into toddler/kid markets while entering infant formula market
- ~65% lower carbon footprint vs global dairy brands
- They are advancing towards a hypoallergenic stamp through clinical study
- #1 Best Seller on Amazon for Baby Cereal category
- Developing liquid products now
- They have a manufacturing partner in the USA and in Europe (this is in process now)
- They are in discussion with additional partners in USA/Canada for powder products and another USA manufacturer for liquid products (this is in process now)
- They anticipate building their own capacity in USA over the next 24 months
- Q4 2022 China (very soon, they will release news about this)
- Q2 2023 Australia
- Q1 to Q4 2023 UK/Germany/France/Italy/Spain/Netherlands/Sweden (Signed an agreement already with a distributor)
Q&A (These are the questions that stood out to me, you are more than welcomed to watch the Webinar to tune in on the rest of the questions)
Q - Do you have any updates on the ready to drink product line?
A - Working on several liquid products for kids and adults for 2023. Finished the development of the kids product line and currently in the development in the adults products. Going to release additional powder products in 2023.
Q - Is Else scaling back on regular toddler formula due to cost compared to omega?
A - No way. We see very strong demand for both products. In fact, the demand for omega toddler formula was so high that we ran out of stock.
Q- Any updates on the buckwheat manufacturing facility? Funds allocated towards it? On-going? Complete? Abandoned?
A - It is alive and working. We continue to manufacture clean buckwheat in the Oregon facility for the infant formula. That was the main purpose of that facility. We have added new suppliers of buckwheat in Europe and in the US. A new partner that can manufacture the hydrolyzed buckwheat that we require so we can reduce the dependency on the European manufacturer. We do not want to be dependent on a single partner.
Q - Is there any insight into the Else acceptance in China?
A - All I can say is stay tuned for the news. It is coming very very soon. It is a matter of days.
My Opinion:
The company is delivering, growing, signing contracts, selling and being overwhelmed by demand, securing production, launching clinical trials, and a best seller on Amazon in less than 6 months. The future is looking very bright for the company. The short sellers are providing serious discounts for shares, they are giving people a great opportunity to buy at a low price. In the future, people will wish they could've bought below $1.00.
Again, always do your due diligence and research before purchasing a stock. This is your money.
